NewsBenzingaIambic Therapeutics: EPS del terzo trimestre $(8,52) delude rispetto alla stima di $(0,72), ricavi a $11,351 milioni deludono rispetto alla stima di $15,133 milioni Iambic Therapeutics: EPS del terzo trimestre $(8,52) delude rispetto alla stima di $(0,72), ricavi a $11,351 milioni deludono rispetto alla stima di $15,133 milioni Benzinga 2026.11.16 13:44 (GMT+0) Open on Benzinga Other news Billionaires Walk Away From Alphabet in Q3 - Hedge Funds Google ‘How to Sell’ and Hit Enter $100 Invested In Visa 15 Years Ago Would Be Worth This Much Today Western Digital Gains, Seagate Flat As Nvidia’s Raised Outlook Lifts AI Storage Hopes Home Depot Posts Strongest Comps In 4 Years, Analysts Revise Price Targets TJ Maxx Parent Bets on Accelerating Sales This Holiday Season Why Is Coinbase Stock Falling on Wednesday?